Edition:
Deutschland

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

66.59EUR
23 Aug 2019
Change (% chg)

€-1.13 (-1.67%)
Prev Close
€67.72
Open
€68.04
Day's High
€68.11
Day's Low
€66.58
Volume
3,337,936
Avg. Vol
3,521,853
52-wk High
€83.73
52-wk Low
€52.02

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Buy/Sell

Sell Hold Buy
2.52 Mean rating from 27 analysts

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

French mayors ban glyphosate weedkiller, defying government

RENNES, France, Aug 22 Some 20 French mayors have banned glyphosate from their municipalities, defying the government, which is now taking legal action to impose national legislation which allows the controversial weedkiller's continued use for now.

Photo

Explainer: What are the obstacles to Bayer settling Roundup lawsuits?

Bayer AG is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

CORRECTED-EXPLAINER-What are the obstacles to Bayer settling Roundup lawsuits?

Aug 22 Bayer AG is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

PRESS DIGEST- Wall Street Journal - Aug 21

Aug 21 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Deals of the day-Mergers and acquisitions

Aug 20 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Photo

Elanco to become No.2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health agreed to buy Bayer's veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion (£6.3 billion), creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online.

Photo

Elanco to become No.2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health agreed to buy Bayer's veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online.

UPDATE 3-Elanco to become No.2 in animal health with $7.6 bln Bayer deal

* Elanco gains strength in e-commerce, tick and flea control (Adds shares, Roundup litigation, Elanco rights issue)

US STOCKS-Wall street set for muted open, retail earnings mixed

* Futures up: Dow 0.05%, S&P 0.03%, Nasdaq 0.07% (Adds comment, details; Updates prices)

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.78%
Rohstoffe -1.40%
Industrie -1.79%
Konjunktur abhängige Waren & Dienstleistungen -0.93%
Konjunktur unabhängige Waren & Dienstleistungen -1.61%
Finanzindustrie -1.75%
Pharma -2.78%
Technologie -0.90%
Telekommunikation -0.70%